Rize Oncology Inc. (RZONF)
| Market Cap | 12.12M |
| Revenue (ttm) | n/a |
| Net Income | -1.22M |
| EPS | -0.02 |
| Shares Out | 75.74M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,000 |
| Open | 0.1600 |
| Previous Close | 0.0004 |
| Day's Range | 0.1600 - 0.1600 |
| 52-Week Range | 0.0004 - 0.1600 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 22, 2026 |
About Rize Oncology
Rize Oncology Inc., a biopharmaceutical company, focuses on the development of precision gene editing for human therapeutics applications. It develops STS-201, a small molecule drug candidate that has exhibited significant utility in soft tissue sarcoma, other types of cancers, and certain proliferative diseases. The company was formerly known as GeneTether Therapeutics Inc. and changed its name to Rize Oncology Inc. in January 2025. Rize Oncology Inc. was founded in 2018 and is based in Kelowna, Canada. [Read more]
Financial Performance
Financial StatementsNews
Rize Oncology Announces Warrant Incentive Program
Kelowna, British Columbia – April 13, 2026 - TheNewswire – Rize Oncology Inc. (the “ Company ”), a clinical-stage pharmaceutical company focused on developing innovative oncology therapeutics, is plea...
Rize Oncology Announces Completion of Private Placement and Resignation of Director
Kelowna, British Columbia--(Newsfile Corp. - November 4, 2025) - Rize Oncology Inc. (OTC: RZONF) (the "Company"), a clinical-stage pharmaceutical company focused on developing innovative oncology ther...